Gilead Sciences (BUE:GILD) FCF Margin % : 27.47% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Gilead Sciences's Free Cash Flow for the three months ended in Dec. 2023 was ARS705,394 Mil. Gilead Sciences's Revenue for the three months ended in Dec. 2023 was ARS2,568,154 Mil. Therefore, Gilead Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was 27.47%.

As of today, Gilead Sciences's current FCF Yield % is 9.11%.

The historical rank and industry rank for Gilead Sciences's FCF Margin % or its related term are showing as below:

BUE:GILD' s FCF Margin % Range Over the Past 10 Years
Min: 27.02 Med: 38.32 Max: 62.82
Current: 27.02

During the past 13 years, the highest FCF Margin % of Gilead Sciences was 62.82%. The lowest was 27.02%. And the median was 38.32%.

BUE:GILD's FCF Margin % is ranked better than
94.83% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs BUE:GILD: 27.02

Gilead Sciences FCF Margin % Historical Data

The historical data trend for Gilead Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences FCF Margin % Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

37.06

30.45

39.57

30.59

27.37

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															32.29	25.74	33.32	23.16	27.47

Competitive Comparison of Gilead Sciences's FCF Margin %

For the Drug Manufacturers - General subindustry, Gilead Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's FCF Margin % falls into.

Gilead Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Gilead Sciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	2678981.003	/	9788876.009
	=	27.37 %

Gilead Sciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	705394.001	/	2568154.002
	=	27.47 %

Gilead Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BUE:GILD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.